SCHEMBL6243789

SCHEMBL6243789

CCCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.53
FAP Q12884 2/20 0.53
DPP8 Q6V1X1 2/20 0.53
DPP9 Q86TI2 2/20 0.53
DPP7 Q9UHL4 2/20 0.53
NPSR1 Q6W5P4 1/20 0.49
XIAP P98170 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
POLB P06746 1/20 0.43
TSHR P16473 1/20 0.43
F2 P00734 1/20 0.41
FKBP5 Q13451 3/20 0.41
FKBP1A P62942 2/20 0.41
OPRM1 P35372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6245876 1.00 DPP4 (0.53) DPP4FAPDPP8DPP9DPP7
SCHEMBL6242775 0.92 NPSR1 (0.59) DPP4FAPDPP8DPP9DPP7
SCHEMBL6242772 0.92 NPSR1 (0.59) DPP4FAPDPP8DPP9DPP7
SCHEMBL6244947 0.91 NPSR1 (0.55) DPP4FAPDPP8DPP9DPP7
SCHEMBL6242559 0.91 NPSR1 (0.55) DPP4FAPDPP8DPP9DPP7
SCHEMBL24648734 0.85 DPP4 (0.50) DPP4FAPDPP8DPP9DPP7
SCHEMBL6241775 0.85 DPP4 (0.52) DPP4FAPDPP8DPP9DPP7
SCHEMBL6241779 0.85 DPP4 (0.52) DPP4FAPDPP8DPP9DPP7
SCHEMBL6242778 0.85 DPP4 (0.47) DPP4FAPDPP8DPP9DPP7
SCHEMBL6242782 0.85 DPP4 (0.47) DPP4FAPDPP8DPP9DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0828851-B1 TRIPEPTIDYLPEPTIDASE INHIBITORS INST NAT SANTE ETDE LA RECH ME (FR) 2005-07-20 EP claimed
US-20030027743-A1 Tripeptidylpeptidase inhibitors INSERM 2003-02-06 US claimed
WO-1996035805-A2 TRIPEPTIDYLPEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1996-11-14 WO claimed
EP-0828851-B1 TRIPEPTIDYLPEPTIDASE INHIBITORS INST NAT SANTE ETDE LA RECH ME (FR) 2005-07-20 EP disclosed
US-20030027743-A1 Tripeptidylpeptidase inhibitors INSERM 2003-02-06 US disclosed
US-6403561-B1 DISORDERS ASSOCIATED WITH THE INACTIVATION OR EXCESSIVE DEGRADATION OF CHOLECYSTOKININ; INHIBITING THE ENZYMATIC HYDROLYSIS OF CHOLECYSTOKININ 1-(2(S)-AMINOBUTYRYL)-2(S)-INDOLINECARBOXYLIC ACID INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2002-06-11 US disclosed
EP-0828851-A2 TRIPEPTIDYLPEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1998-03-18 EP disclosed
WO-1996035805-A2 TRIPEPTIDYLPEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1996-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030027743-A1 Tripeptidylpeptidase inhibitors DPP4, DPP3, DPP9 DPP4 1/4885FAP 25/4885DPP8 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.